Monopar Therapeutics Inc. (MNPR)

0.6780 +0.0280 (+4.31%) At close: 04:00PM EDT

Monopar Therapeutics Inc.

1000 Skokie Boulevard
Suite 350
Wilmette, IL 60091
United States
847 388 0349
https://www.monopartx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc	Co-Founder, CEO, President & Director	710.5k	N/A	1984
Ms. Kim R. Tsuchimoto CPA	CFO, Secretary, Treasurer & Director	354k	N/A	1963
Mr. Andrew J. Cittadine M.B.A.	Chief Operating Officer	416.7k	N/A	1973
Dr. Patrice P. Rioux M.D., Ph.D.	Acting Chief Medical Officer	N/A	N/A	1951

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Corporate Governance

Monopar Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.